Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.

@article{Oparil2010TripleTW,
  title={Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.},
  author={Suzanne Oparil and Michael R. Melino and James H F Lee and V{\'i}ctor L. Fern{\'a}ndez and Reinilde Heyrman},
  journal={Clinical therapeutics},
  year={2010},
  volume={32 7},
  pages={1252-69}
}
BACKGROUND Patients with hypertension may require a combination of > or =2 antihypertensive agents to achieve blood pressure (BP) control. OBJECTIVE The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension. METHODS This was a multicenter, randomized… CONTINUE READING